title: Do TNF-blockers reduce or induce uveitis?
authors.forename: T
authors.initials: T
authors.lastname: Cobo-Ibáñez
authors.forename: M
authors.initials: M
authors.lastname: del Carmen Ordóñez
authors.forename: S
authors.initials: S
authors.lastname: Muñoz-Fernández
authors.forename: R
authors.initials: R
authors.lastname: Madero-Prado
authors.forename: E
authors.initials: E
authors.lastname: Martín-Mola
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012189:Retrospective Studies; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000209:etiology*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept